Mirum Pharmaceuticals stock surged 25% and how LIVMARLI drives growth. Explore future prospects with Volixibat. Click here to ...
Zacks Investment Research on MSN9d
Mirum's Heavy Dependence on Livmarli for Revenues Remains a WoeMirum Pharmaceuticals’ MIRM lead product, Livmarli (maralixibat), an orally administered ileal bile acid transporter (“IBAT”) ...
LIVMARLI is the first and only treatment available for cholestatic pruritus in patients with Alagille syndrome and ...
Hosted on MSN4mon
Mirum Shares Surge More Than 90% in 6 Months: Here's WhyIn the past 60 days, estimates for Immunocore’s 2024 loss per share have narrowed from $1.79 to 94 cents. Loss per share estimates for 2025 have narrowed from $2.35 to $1.57 during the same time ...
LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with ...
The once-daily, non-systemic ileal bile acid transport (IBAT) inhibitor was recommended for approval by the EMA's human medicines committee, the CHMP, in July 2023 for this indication under the ...
A replay of this webcast will be available for 30 days. About Mirum Pharmaceuticals LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults.
LIVMARLI® (maralixibat) oral solution is an orally administered, ileal bile acid transporter (IBAT) inhibitor approved by the U.S. Food and Drug Administration and European Medicines Agency for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback